15 September 2016 - Eisai announced that its European regional headquarters Eisai Europe has received license from the European Commission for anti-cancer agent Kisplyx (lenvatinib mesylate) in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor targeted therapy.

Following the United States, Europe marks the second region where lenvatinib has been licensed for the advanced renal cell carcinoma indication.

Read Eisai press release